Stockscreener 앱 받기
65.96
0.96%
0.536
전일 마감가:
$65.42
열려 있는:
$65.35
하루 거래량:
1.20M
Relative Volume:
0.50
시가총액:
$10.50B
수익:
$705.14M
순이익/손실:
$-453.90M
주가수익비율:
-21.70
EPS:
-3.04
순현금흐름:
$-551.29M
1주 성능:
+3.30%
1개월 성능:
+54.92%
6개월 성능:
+142.30%
1년 성능:
+69.06%
1일 변동 폭
$64.92
$66.14
1주일 범위
$62.72
$66.14
52주 변동 폭
$23.95
$66.14
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
IONS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
65.87 | 10.43B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.02 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.55 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.94 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
772.15 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.87 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2025-09-03 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 개시 | H.C. Wainwright | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Neutral |
| 2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 재개 | Jefferies | Buy |
| 2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Ionis Pharmaceuticals stock hits 52-week high at 64.89 USD By Investing.com - Investing.com Nigeria
What analysts say about Ionis Pharmaceuticals Inc ISI stockDividend Stock Watch & High Return Wealth Plans - earlytimes.in
Alnylam and Ionis Pharmaceuticals are the leading companies - openPR.com
Applying big data sentiment scoring on Ionis Pharmaceuticals Inc.2025 Historical Comparison & Risk Controlled Stock Pick Alerts - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock in buy zone after pullbackWeekly Market Summary & Expert-Curated Trade Recommendations - newser.com
Why ETFs are accumulating Ionis Pharmaceuticals Inc. (ISI) stockPortfolio Gains Report & Comprehensive Market Scan Reports - newser.com
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Investor Ratings Indicate Promising Upside Potential - DirectorsTalk Interviews
Published on: 2025-09-29 03:15:49 - newser.com
What drives Ionis Pharmaceuticals Inc stock priceVolume Weighted Average Price & Minimal Investment Profits - earlytimes.in
Assenagon Asset Management S.A. Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Should you hold or exit Ionis Pharmaceuticals Inc. nowQuarterly Market Review & Real-Time Volume Trigger Notifications - newser.com
Using fundamentals and technicals on Ionis Pharmaceuticals Inc.Trade Volume Report & Risk Controlled Daily Trade Plans - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock a fit for income portfoliosJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com
Ionis Pharmaceuticals (IONS) Is Up 5.0% After Positive Phase III Results for Alexander Disease Therapy - Yahoo Finance
IONS Upgraded by Goldman Sachs with a Significant Price Target I - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Rating Increased to Neutral at The Goldman Sachs Group - MarketBeat
Leerink Partnrs Has Positive Outlook of IONS FY2025 Earnings - MarketBeat
Goldman Sachs Upgrades Ionis Pharmaceuticals to Neutral From Sell, Adjusts PT to $65 From $45 - MarketScreener
Ionis chalks up rare disease win with zilganersen - The Pharma Letter
Is Ionis Pharmaceuticals Inc. meeting your algorithmic filter criteria2025 Buyback Activity & Entry Point Confirmation Alerts - newser.com
Morgan Stanley Raises Ionis Pharmaceuticals (IONS) Price Target to $86 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals stock price target raised to $68 by Leerink Partners - Investing.com UK
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal - sharewise.com
Hereditary Angioedema Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Ionis Pharmaceuticals Larger Than S&P 500 Component Align Technology - Nasdaq
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen - Biogen
A Look at Ionis Pharmaceuticals’s Valuation as Zilganersen Delivers Breakthrough Results in Alexander Disease - Sahm
Biotech Stocks Rally. 3 Favorite Plays From the Charts. - Barron's
Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study - MedCity News
Barclays Maintains Overweight Rating on IONS, Raises Price Targe - GuruFocus
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease - Stocktwits
Guggenheim Raises Ionis Pharmaceuticals (IONS) Price Target to $92 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (IONS): Analyst Rating Update and Target P - GuruFocus
Guggenheim Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $83.00 at Bank of America - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease - BioSpace
IONS: HC Wainwright Reiterates Buy Rating with $95 Target | IONS Stock News - GuruFocus
Ionis reports positive results for Alexander disease drug zilganersen By Investing.com - Investing.com Nigeria
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease - BioSpace
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Sovran Advisors LLC - MarketBeat
Ionis Targets Ultra-Rare Disease Market With Zilganersen - insights.citeline.com
Ionis reports positive results for Alexander disease drug zilganersen - Investing.com India
Ionis says RNA drug for rare brain disorder succeeded pivotal trial, plans to ask for FDA approval - Endpoints News
Ionis stock surges after positive results from Alexander disease drug By Investing.com - Investing.com Canada
Ionis reports promising data from study of Alexander disease therapy - Seeking Alpha
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial - Benzinga
Hereditary Angioedema Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
Ionis Pharmaceuticals (IONS) Reveals Promising Results for Zilga - GuruFocus
Ionis Pharma Reports Positive Topline Results From Pivotal Study Of Zilganersen In Alexander Disease - Nasdaq
Ionis' brain disorder drug shows promise in clinical trial - TradingView
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
자본화:
|
볼륨(24시간):